On the stock market since 2014, it operates in the world of health and science. It has 8 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 52 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $30.00 — 285% above today’s price.
A loss of $17.3M against $0 in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, AKTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AKTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (6/100) says the stock isn’t cheap.